NAGE
Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.99
−0.17%Sep 17, 2026, 12:32 UTC
Niagen Bioscience's wholly owned subsidiary NAD Pharmaceuticals Corp. engaged life sciences advisory firm Red Sky Partners to support advancement of its investigational drug candidate NB4168.
Source:Sep 10, 2026, 12:32 UTC
Niagen Bioscience announced that CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity's Well Summit in New York from September 28 to 30, 2026.
Source:Aug 20, 2026, 12:32 UTC
Niagen Bioscience announced that its Tru Niagen supplement is now available at GNC and Sam's Club retail locations and online.
Source:Aug 4, 2026, 20:02 UTC
Niagen Bioscience, Inc. reported second quarter 2026 financial results with total net sales of $29.8 million and net income of $1.0 million.
Jul 13, 2026, 12:34 UTC
NIAGEN's drug NB4168 received FDA Rare Pediatric Disease designation.
Source:Jun 2, 2026, 12:32 UTC
Niagen Bioscience renamed the ChromaDex External Research Program to the Niagen Research Program.